Observational Registry of Patients With Rheumatoid Arthritis /Spondyloarthritis Using Biological or Targeted Synthetic DMARDs

计划入组 1,400 人 · 首次发布于 2019 年 10 月 25 日

A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis

计划入组 21,340 人 · 首次发布于 2024 年 5 月 17 日

Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs

计划入组 100 人 · 首次发布于 2019 年 9 月 4 日

DMARDs

TAR-001

Synthetic camphor(Anbesol Cold Sore Therapy, Flexall Ultra Plus, Icy Hot Arthritis, Ivy-dry Cream, Jointflex, Men-phor, Ortho-nesic, Salonpas Pain Relieving Patch, Sarna Sensitive, Tiger Balm, Vaporex, Vicks Vaporub, Vicks Vaposteam)

C₁₀H₁₆O

SYNTHETIC BIOLOGICS INC

United States

DELTA SYNTHETIC CO., LTD.

Taiwan

TARGETED GENETICS CORPORATION

United States

FDA Approves First Neuroimmune Modulation Device for Rheumatoid Arthritis Treatment

SetPoint Medical's Neuroimmune Modulation Platform Receives EULAR Clinical Research Award for Rheumatoid Arthritis Trial

NSF Awards $500K Grant to Advance Synthetic DNA Nanoparticles for Targeted Gene Therapy